BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31813475)

  • 21. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
    Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
    Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
    Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
    J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis and Biological Evaluation of Novel Urea and Thiourea Bearing thieno[3,2-d]-pyrimidines as PI3 Kinase Inhibitors.
    Bodige S; Ravula P; Gulipalli KC; Endoori S; Chandra JNNS; Cherukumalli PKR; Vanaja G R ; Seelam N
    Anticancer Agents Med Chem; 2018; 18(6):891-902. PubMed ID: 29424321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
    Ahmed EY; Elserwy WS; El-Mansy MF; Serry AM; Salem AM; Abdou AM; Abdelrahman BA; Elsayed KH; Abd Elaziz MR
    Bioorg Med Chem Lett; 2021 Sep; 48():128258. PubMed ID: 34246754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates.
    Khan I; Tantray MA; Hamid H; Sarwar Alam M; Sharma K; Kesharwani P
    Bioorg Chem; 2022 Feb; 119():105512. PubMed ID: 34861627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
    El-Ansary AK; Kamal AM; Al-Ghorafi MA
    Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
    Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
    Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and preclinical evaluation of 5-methyl-N
    Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
    Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
    Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C
    Oh C; Kim H; Kang JS; Yun J; Sim J; Kim HM; Han G
    Bioorg Med Chem Lett; 2017 Feb; 27(3):496-500. PubMed ID: 28043794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.
    El-Metwally SA; Khalil AK; El-Sayed WM
    Bioorg Chem; 2020 Jan; 94():103492. PubMed ID: 31864673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.